Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I Diabetes

NCT00064714 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

47

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus

Interventions

DRUG: AC2993 (exenatide)
DRUG: daclizumab (immunosuppressive)

Sponsor

AstraZeneca

Collaborators

[object Object]